Prostate Cell News Volume 7.12 | Apr 8 2016

SOX9 Drives WNT Pathway Activation in Prostate Cancer
The authors performed SOX9 ChIP sequencing analysis and transcriptome profiling of prostate cancer cells and determined that SOX9 positively regulates multiple WNT pathway genes, including those encoding WNT receptors and the downstream β-catenin effector TCF4. [J Clin Invest] Full Article

Prostate Epithelial Cell of Origin Determines Cancer Differentiation State in an Organoid Transformation Assay
Investigators transduced primary human prostate basal and luminal cells with lentiviruses expressing c-Myc and activated AKT1 (myristoylated AKT1 or myrAKT1) to mimic the MYC amplification and PTEN loss commonly detected in human prostate cancer. [Proc Natl Acad Sci USA] Full Article

Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could Be an Alternative Treatment to Flutamide
Investigators wanted to compare or combine a developed siRNA to flutamide (FLU), one of the gold-standard treatment of prostate cancer. Therefore, concomitant or subsequent association of FLU to siRNA TMPRSS2-ERG was performed in VCaP cells and in SCID mice bearing xenografted VCaP tumors. [Mol Ther Nucleic Acids] Full Article

SOCS3 Modulates the Response to Enzalutamide and Is Regulated by AR Signaling and CpG Methylation in Prostate Cancer Cells
Researchers revealed that the suppressor of cytokine signaling 3 (SOCS3) promoter is hypermethylated in cancerous regions compared to adjacent benign tissue in prostate cancer using methylation-specific qPCR. [Mol Cancer Res] Abstract | Full Article

Immunogenicity and Efficacy of the Novel Cancer Vaccine Based on Simian Adenovirus and MVA Vectors Alone and in Combination with PD-1 mAb in a Mouse Model of Prostate Cancer
Scientists explored the immunogenic properties and protective efficacy of a novel prostate cancer immunotherapy based on the heterologous prime-boost viral-vectored vaccination platform. [Cancer Immunol Immunother] Full Article

Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth
The authors sought to create a promising gene therapy approach that co-targets cancer and its supporting stromal cells for combating castration-resistant prostate tumors. [PLoS One] Full Article

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
Investigators explored co-targeting of pathways in androgen receptor-positive prostate cancer models. Using various in vitro models of prostate cancer disease states including androgen dependent, castrate resistant prostate cancer and ENZ-resistant prostate cancer, they evaluated the relevance of targeting both AKT and MEK pathways. [PLoS One] Full Article

CLINICAL RESEARCH

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy with or without Bevacizumab for Patients with Recurrent Prostate Cancer after Definitive Local Therapy
The purpose of this randomized Phase II trial was to investigate the efficacy and toxicity of short-course androgen deprivation therapy with or without bevacizumab in men with hormone-sensitive prostate cancer. [J Clin Oncol] Abstract

Androgen-Deprivation Therapy Plus Chemotherapy in Metastatic Hormone-Sensitive Prostate Cancer. A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Scientists assessed the efficacy and toxicity of androgen-deprivation therapy plus chemotherapy in patients with hormone-sensitive metastatic prostate cancer. [Urol Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Janssen Enters Worldwide Collaboration and License Agreement with TESARO, Inc., for Niraparib in Prostate Cancer
Janssen Biotech, Inc. announced it has entered a worldwide collaboration and license agreement with TESARO, Inc., for exclusive rights to the investigational compound niraparib in prostate cancer. [Janssen Pharmaceutical Companies] Press Release

Precision Biopsy Submits Investigational Device Exemption (IDE) Application to the FDA to Expand Clinical Trial of Its ClariCore™ Biopsy System in Prostate Cancer Patients
Precision Biopsy announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for permission to enroll patients in the Transrectal Ultrasound and MR/Fusion arm of the company’s study, expanding the scope of a clinical trial for its ClariCore™ Biopsy System in prostate cancer patients. [Precision Biopsy] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

PhD Studentship – Vesicles to Target Prostate Cancer Metastasis (University of East Anglia)

PhD Studentship – Various Projects (Cancer Research UK Manchester Institute)

Clinical Research Fellow – Prostate Cancer Vaccine (University of Oxford)

Lead Scientist – Prostate Cancer (Memorial Sloan Kettering Cancer Center)

Postdoctoral Fellowship – Castration Resistant Prostate Cancer (University of Florida)

PhD Studentship – Wnt Signaling in Stem Cells and Cancer (German Cancer Research Center)

Postdoctoral Fellowship – Prostate and Breast Cancer Molecular Mechanisms (Feinberg School of Medicine)

Tenure Track Faculty Positions – Various Methods in Cancer Biology (Paul L. Foster School of Medicine)

Research Group Leader – Stress Regulated Processes During Oncogenesis (INSERM)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.